Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026
Biotechnology
-
-
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
September 11, 2026
-
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical’s FDA-Cleared Robotic TMS System
September 11, 2026
-
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol “EOCN” to Reflect its New Dawn Platform for GI Innovation
September 9, 2026
-
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
September 4, 2026
-
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 3, 2026
-
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
September 1, 2026
-
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 1, 2026
-
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
August 31, 2026
-
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026
-
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
August 28, 2026
-
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
August 28, 2026
-
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
August 21, 2026
-
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
August 21, 2026
-
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 14, 2026
-
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
August 13, 2026